Mounjaro Launch Fuels Surge in Brazilian Pharmacy Sales as GLP-1 Battle Intensifies
Eli Lilly's tirzepatide, Mounjaro, has become a high-margin sales driver for major Brazilian pharmacy chains like Raia Drogasil.
The official arrival of Eli Lilly’s high-demand drug Mounjaro (tirzepatide) in Brazilian pharmacies has begun driving revenue for the country’s largest retail distributors, solidifying a thematic shift toward high-margin pharmaceutical sales across the sector. Mounjaro, considered the next generation in a class of medications used for diabetes and popular for weight loss, was approved by the National Health Surveillance Agency (Anvisa) in late 2023 and became available in the following year, creating a new source of growth for distributors like Raia Drogasil (RD Saúde).
Mounjaro’s blockbuster status stems from its action as a dual-agonist, targeting not only the Glucagon-like peptide-1 (GLP-1) receptor—the mechanism used by its predecessor, Ozempic (semaglutide)—but also the glucose-dependent insulinotropic polypeptide (GIP) receptor. This dual-receptor engagement provides superior results in both blood sugar control and weight reduction in clinical trials, leading to immediate high demand in Brazil’s private health market. While the drug is approved for Type 2 Diabetes, it is frequently prescribed “off-label” for weight loss, creating a supply strain and driving sales for any retailer able to stock the product. The rush has even spurred political debate, with lawmakers considering measures that would allow Brazil to issue a compulsory license for the drug to lower its high cost and increase accessibility.
For the Brazilian retail landscape, which is dominated by major players, the new class of expensive injectables represents a significant financial lift. Raia Drogasil, the country’s largest pharmacy chain with close to 3,000 stores nationwide, has seen the impact directly. The company reported in late 2025 that the demand for GLP-1 drugs was a major factor fueling a 12.7% climb in gross revenue. The superior pricing and demand for new medications like tirzepatide are allowing chains like Raia Drogasil and Panvel to capitalize on an expanding market.
The surge highlights a pharmaceutical segment that has become a key battleground for global drug makers. The total market for "slimming pens" in Brazil surged to R$13.2 billion (approximately $2.5 billion) in the year ending August 2025, with market leadership shifting rapidly as Eli Lilly’s Mounjaro directly challenges the previous dominance of Novo Nordisk’s semaglutide products. The continued competition to meet that demand, paired with the high price point of these innovative treatments, ensures that pharmacy chains with strong distribution networks will remain key beneficiaries in the immediate future.
What it touches The explosive demand for Mounjaro directly benefits the publicly traded Brazilian retail pharmacy sector, where high-margin pharmaceutical sales are a key growth driver. This includes market leaders such as Raia Drogasil S.A. (B3: RADL3) and Panvel (B3: PNVL3), which distribute the high-value medication and whose revenue is closely tied to the sales volume of these new-generation, innovative treatments.